Spike Protein News and Research

RSS

Study estimates impact of amino acid changes on SARS-CoV-2 infection

New research led by Costas D. Maranas from The Pennsylvania State University predicts amino acid changes to the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein would negatively impact binding affinity and subsequent infection into human cells.

31 Mar 2021

Study reports on two cats that caught COVID-19

Our feline friends are also vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to new research posted to the preprint server bioRxiv. The researchers diagnosed two cats living in France with mild symptomatic COVID-19 illness. The virus was most likely transmitted from their owners.

31 Mar 2021

New Phase 1 clinical trial of investigational vaccine against B.1.351 SARS-CoV-2 variant begins

An investigational vaccine designed to protect against the B.1.351 SARS-CoV-2 variant has been administered as part of a new Phase 1 clinical trial evaluating the vaccine candidate's safety and immunogenicity in adult volunteers.

31 Mar 2021

Tamper-proof temperature indicator could help monitor ideal storage conditions of mRNA vaccines

Scientists have developed vaccines for COVID-19 with record speed. The first two vaccines widely distributed in the U.S. are mRNA-based and require ultracold storage (-70 C for one and -20 C for the other).

31 Mar 2021

B.1.1.7 rapidly becoming the dominant SARS-CoV-2 variant in the United States

The faster-spreading B.1.1.7 variant of SARS-CoV-2 first detected in the United Kingdom, the coronavirus that causes COVID-19, is quickly on its way to becoming the dominant variant of the virus in the United States, according to a study from scientists at Scripps Research and the COVID-19 test maker Helix.

31 Mar 2021

Asymmetrical vaccine distribution could promote vaccine evading mutations in SARS-CoV-2

Researchers have investigated the ultimate influence of unequal vaccine distribution by mathematical modeling, revealing the critical role of fair distribution in future COVID-19 containment strategy.

31 Mar 2021

NIAID researchers identify key player in the immune response to SARS-CoV-2

When variants of SARS-CoV-2 (the virus that causes COVID-19) emerged in late 2020, concern arose that they might elude protective immune responses generated by prior infection or vaccination, potentially making re-infection more likely or vaccination less effective.

31 Mar 2021

Development of a model of substrate coordination to Zn-bound ACE2

The ongoing coronavirus disease-19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has claimed more than 2.8 million lives worldwide. Authorities are facing difficulty in preventing the spread of disease due to the highly infectious nature of SARS-CoV-2. Therefore, reducing the virus's ability to infect an individual's respiratory epithelial cells could prove an effective measure to prevent disease transmission.

31 Mar 2021

Study of twins reveals differences in adaptive immunity towards SARS-CoV-2

Twins may look alike on the outside, but not so much on the inside. That's one takeaway from a new preprint study posted to the medRxiv server where Brazilian researchers observed different T-cell responses in two pairs of identical twins exposed to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One twin who was reinfected with SARS-CoV-2 four months after had low recognition of CD4+ and CD8+ T-cell epitopes.

31 Mar 2021

New coronavirus variant with E484K mutation detected in Arizona

Arizona joins the ever-growing list of American states harboring a variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A study led by Efrem S. Lim of Arizona State University confirms evidence of the B.1.243.1 with an E484K mutation on the spike protein.

30 Mar 2021

SARS-CoV-2 mutation T478K spreading at alarming speed in Mexico

Several SARS-CoV-2 variants have emerged, posing a renewed threat to COVID-19 containment and to vaccine and drug efficacy. In this study, we analyzed more than 820,000 SARS-CoV-2 genomic sequences deposited up to March 26, 2021 and identified a novel T478K mutation located on the SARS-CoV-2 Spike protein.

30 Mar 2021

Comparing the transmission routes of two SARS-CoV-2 variants of concern

The research team had previously identified the UK variant as having higher viral RNA shedding than the D614G variant. However here, they wanted to compare the transmission of such variants through different routes of potential infection: direct contact, aerosol (airborne droplets), and fomite (objects which may be contaminated and therefore spread infectious agents).

30 Mar 2021

Microbiota-derived molecules do not change the entry or replication of SARS-CoV-2 in intestinal cells

A study conducted at the University of Campinas in the state of São Paulo, Brazil, shows that compounds produced by gut microbiota (bacteria and other microorganisms) during fermentation of insoluble fiber from dietary plant matter do not affect the ability of the novel coronavirus SARS-CoV-2 to enter and replicate in cells lining the intestines.

30 Mar 2021

Researchers examine the evolutionary race between SARS-CoV-2 and human defenses

Researchers have analyzed this evolution of the virus based on evolutionary ecology theory. Using the virus genomes available in the Global Initiative on Sharing Avian Influenza Data (GISAID) database, the researchers focused their inquiry on mutations in the receptor-binding domain (RBD) on the spike protein of SARS-CoV-2.

30 Mar 2021

Study finds rapid increase in IgG and IgA antibody levels following COVID-19 mRNA vaccination

A new study describes the kinetics of the antibody response to the earliest approved vaccines against COVID-19, which were developed on an mRNA platform.

30 Mar 2021

Researchers report on novel SARS-CoV-2 Israeli strain with unique spike glycoprotein

Researchers from Israel describe a novel SARS-CoV-2 strain with a non-synonymous mutation in its spike glycoprotein, designated as P681H; nevertheless, its emergence has not been associated with increased infections rate, facilitated spread or vaccine evasion.

30 Mar 2021

Nanoparticles elicit neutralizing antibodies to diverse SARS-CoV-2 variants

Spike-protein-based nanoparticle vaccine candidates were retained longer in follicular dendritic cells and showed higher germinal center reactions in lymph node follicles compared to soluble spike protein vaccine.

30 Mar 2021

Vaccine-induced 2C08 antibody protects against SARS-CoV-2 variants

A new preprint study posted to the bioRxiv* server led by Ali H. Ellebedy from the Washington University School of Medicine found that the monoclonal antibody 2C08 produced by the Pfizer vaccine could help neutralize COVID-19 variants.

29 Mar 2021

Have scientists found SARS-CoV-2's Achilles' heel?

Have scientists uncovered the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Achille's heel? New preclinical research from Cell neutralizing antibodies targeting the N-terminal domain of the coronavirus could be a potential target for antibodies to bind and effectively neutralize SARS-CoV-2.

29 Mar 2021

New study reports increased spread of B.1.1.7 variant in Houston, Texas

Research led by Jimmy Gollihar from the CCDC Army Research Laboratory-South in Austin, Texas found the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.1.7 —first detected last fall in England — increased in Houston, Texas. The B.1.1.7 variant is rapidly spreading with a case doubling time of 6.9 days.

29 Mar 2021